<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">World J. Gastroenterol</journal-id><journal-id journal-id-type="publisher-id">WJG</journal-id><journal-title-group><journal-title>World Journal of Gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">1007-9327</issn><issn pub-type="epub">2219-2840</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5037089</article-id><article-id pub-id-type="other">jWJG.v22.i36.pg8203</article-id><article-id pub-id-type="doi">10.3748/wjg.v22.i36.8203</article-id><article-categories><subj-group subj-group-type="heading"><subject>Retrospective Study</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Clinicopathological features of alpha-fetoprotein producing early gastric cancer with enteroblastic differentiation </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Matsumoto</surname><given-names>Kohei</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ueyama</surname><given-names>Hiroya</given-names></name></contrib><contrib contrib-type="author"><name><surname>Matsumoto</surname><given-names>Kenshi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Akazawa</surname><given-names>Yoichi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Komori</surname><given-names>Hiroyuki</given-names></name></contrib><contrib contrib-type="author"><name><surname>Takeda</surname><given-names>Tsutomu</given-names></name></contrib><contrib contrib-type="author"><name><surname>Murakami</surname><given-names>Takashi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Asaoka</surname><given-names>Daisuke</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hojo</surname><given-names>Mariko</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tomita</surname><given-names>Natsumi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nagahara</surname><given-names>Akihito</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kajiyama</surname><given-names>Yoshiaki</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Takashi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>Sumio</given-names></name></contrib><aff>Kohei Matsumoto, Hiroya Ueyama, Kenshi Matsumoto, Yoichi Akazawa, Hiroyuki Komori, Tsutomu Takeda, Takashi Murakami, Daisuke Asaoka, Mariko Hojo, Sumio Watanabe, Department of Gastroenterology, Juntendo University School of Medicine, Tokyo 113-8421, Japan</aff><aff>Natsumi Tomita, Yoshiaki Kajiyama, Department of Esophageal and Gastroenterological Surgery, Juntendo University School of Medicine, Tokyo 113-8421, Japan</aff><aff>Akihito Nagahara, Department of Gastroenterology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan</aff><aff>Takashi Yao, Department of Pathology, Juntendo University School of Medicine, Tokyo 113-8421, Japan</aff></contrib-group><author-notes><fn><p><text><SENT sid="1" pm="."><plain>Author contributions: Matsumoto K and Ueyama H designed and performed the study and wrote the paper; Akazawa Y, Komori H, Takeda T, Murakami T, Asaoka D and Hojo M performed research; Matsumoto Kenshi, Tomita N, Kajiyama Y, Yao T, Nagahara A and Watanabe S critically revised the manuscript. </plain></SENT>
</text></p><p><text><SENT sid="2" pm="."><plain>Correspondence to: Kohei Matsumoto, MD, Department of Gastroenterology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan. khmatsu@juntendo.ac.jp </plain></SENT>
</text></p><p><text><SENT sid="3" pm="."><plain>Telephone: +81-3-58021058 Fax: +81-3-38138862 </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><day>28</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>28</day><month>9</month><year>2016</year></pub-date><volume>22</volume><issue>36</issue><fpage>8203</fpage><lpage>8210</lpage><history><date date-type="received"><day>15</day><month>3</month><year>2016</year></date><date date-type="rev-recd"><day>25</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>8</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>Â©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</license-p></license></permissions><abstract><sec><title><text><SENT sid="4" pm="."><plain>AIM </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>To investigate clinicopathological features of early stage gastric cancer with enteroblastic differentiation (GCED). </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="6" pm="."><plain>METHODS </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>We retrospectively investigated data on 6 cases of early stage GCED and 186 cases of early stage conventional gastric cancer (CGC: well or moderately differentiated adenocarcinoma) who underwent endoscopic submucosal dissection or endoscopic mucosal resection from September 2011 to February 2015 in our hospital. </plain></SENT>
<SENT sid="8" pm="."><plain>GCED was defined as a tumor having a primitive intestine-like structure composed of cuboidal or columnar cells with clear cytoplasm and immunohistochemical positivity for either alpha-fetoprotein, Glypican 3 or SALL4. </plain></SENT>
<SENT sid="9" pm="."><plain>The following were compared between GCED and CGC: age, gender, location and size of tumor, macroscopic type, ulceration, depth of invasion, lymphatic and venous invasion, positive horizontal and vertical margin, curative resection rate. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="10" pm="."><plain>RESULTS </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>Six cases (5 males, 1 female; mean age 75.7 years; 6 lesions) of early gastric cancer with a GCED component and 186 cases (139 males, 47 females; mean age 72.7 years; 209 lesions) of early stage CGC were investigated. </plain></SENT>
<SENT sid="12" pm="."><plain>Mean tumor diameters were similar but rates of submucosal invasion, lymphatic invasion, venous invasion, and non-curative resection were higher in GCED than CGC (66.6% vs 11.4%, 33.3% vs 2.3%, 66.6% vs 0.4%, 83.3% vs 11% respectively, P &lt; 0.01). </plain></SENT>
<SENT sid="13" pm="."><plain>Deep submucosal invasion was not revealed endoscopically or by preoperative biopsy. </plain></SENT>
<SENT sid="14" pm="."><plain>Histologically, in GCED the superficial mucosal layer was covered with a CGC component. </plain></SENT>
<SENT sid="15" pm="."><plain>The GCED component tended to exist in the deeper part of the mucosa to the submucosa by lymphatic and/or venous invasion, without severe stromal reaction. </plain></SENT>
<SENT sid="16" pm="."><plain>In addition, Glypican 3 was the most sensitive marker for GCED (positivity, 83.3%), immunohistochemically. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="17" pm="."><plain>CONCLUSION </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="18" pm="."><plain>Even in the early stage GCED has high malignant potential, and preoperative diagnosis is considered difficult. </plain></SENT>
<SENT sid="19" pm="."><plain>Endoscopists and pathologists should know the clinicopathological features of this highly malignant type of cancer. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group><kwd>Alpha-fetoprotein-producing gastric cancer</kwd><kwd>Gastric cancer with enteroblastic differentiation</kwd><kwd>Early gastric cancer</kwd><kwd>Glypican 3</kwd><kwd>SALL4</kwd></kwd-group></SecTag></article-meta></front><body><p><text><SENT sid="20" pm="."><plain>Core tip: We evaluated the comparison of clinicopathological features between 6 cases of early stage gastric cancer with enteroblastic differentiation (GCED) and 186 cases of early stage conventional gastric cancer (CGC: well/ moderately differentiated adenocarcinoma). </plain></SENT>
<SENT sid="21" pm="."><plain>Lymphatic, venous, and submucosal invasion rates were higher in GCED than CGC (33.3% vs 2.3%, 66.6% vs 0.4%, 66.6% vs 11.4% respectively, P &lt; 0.01). </plain></SENT>
<SENT sid="22" pm="."><plain>In addition, Glypican 3 was the most sensitive marker for GCED (positivity, 83.3%), immunohistochemically. </plain></SENT>
<SENT sid="23" pm="."><plain>GCED has high malignant potential even at an early stage, and preoperative diagnosis is considered difficult. </plain></SENT>
<SENT sid="24" pm="."><plain>Further investigations are needed to establish optimal treatment approaches for GCED. </plain></SENT>
</text></p><SecTag type="INTRO"><sec><title><text><SENT sid="25" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="26" pm="."><plain>Gastric cancer with enteroblastic differentiation (GCED) was proposed as a very rare variant of alpha-fetoprotein-producing gastric cancer (AFPGC) and its clinicopathological features have not been well elucidated. </plain></SENT>
<SENT sid="27" pm="."><plain>There are few reports about GCED, and most are case reports. </plain></SENT>
<SENT sid="28" pm="."><plain>In these earlier reported cases, GCED was histologically characterized as having a primitive intestine-like structure composed of cuboidal or columnar cells with clear cytoplasm[1-3]. </plain></SENT>
<SENT sid="29" pm="."><plain>Murakami et al[4] reported 29 cases of GCED in which stages ranged from an early to an advanced stage based on clinicopathologic and immunohistochemical characteristics. </plain></SENT>
<SENT sid="30" pm="."><plain>They proposed that GCED showed aggressive behavior such as lymphatic and venous invasion, lymph node metastasis, and liver metastasis, and its clinicopathologic features were similar to those of AFPGC. </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>Recently, with the advent and widespread use of endoscopic submucosal dissection (ESD), indications for endoscopic treatment of early stage gastric cancer have been expanding rapidly. </plain></SENT>
<SENT sid="32" pm="."><plain>Therefore, it is necessary for endoscopists to know the clinicopathological features of various histological types of early gastric cancer. </plain></SENT>
<SENT sid="33" pm="."><plain>However, no report has focused on the early stage of GCED. </plain></SENT>
<SENT sid="34" pm="."><plain>This study aimed to clarify the clinicopathological features of early stage GCED by comparisons with the early stage of conventional gastric cancer (CGC), including well or moderately differentiated carcinoma. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods"><title><text><SENT sid="35" pm="."><plain>MATERIALS AND METHODS </plain></SENT>
</text></title><p><text><SENT sid="36" pm="."><plain>This study was conducted in accordance with the Declaration of Helsinki and was approved by the Juntendo University School of Medicine Institutional Review Board. </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>All procedures were recorded in endoscopy databases on cases that underwent endoscopic resection in our hospital. </plain></SENT>
<SENT sid="38" pm="."><plain>The databases were examined to identify all cases of early stage GCED and CGC that underwent ESD or endoscopic mucosal resection from September 2011 to February 2015. </plain></SENT>
<SENT sid="39" pm="."><plain>We evaluated the comparison between early gastric cancer with a GCED component and early stage CGC clinicopathologically. </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>GCED was defined as a tumor having a primitive intestine-like structure composed of cuboidal or columnar cells with clear cytoplasm and immunohistochemical positivity for either alpha-fetoprotein (AFP) (rabbit polyclonal, 1:1000; Dako, Glostrup, Denmark), Glypican 3 (clone 1G12, 1:200; BioMosaics, Burlington, VT, United States) or SALL4 (clone 6E3, 1:100; Abnova, Taipei, Taiwan). </plain></SENT>
<SENT sid="41" pm="."><plain>Results of histology and immunohistochemical staining were evaluated by two pathologists specialized in the gastrointestinal tract. </plain></SENT>
<SENT sid="42" pm="."><plain>We determined curative resection criteria according to Gastric Cancer Treatment Guidelines 2010 or 2014 provided by the Japanese Gastric Cancer Association[5,6]. </plain></SENT>
</text></p><p><text><SENT sid="43" pm="."><plain>Statistical analyses were conducted using SPSS (version 15.0 for Windows; SPPS Inc., Chicago, IL, United States) software. </plain></SENT>
<SENT sid="44" pm="."><plain>The comparison of clinicopathological features between GCEDs and CGCs were examined by the Ï2 test and the Mann-Whitney U test. </plain></SENT>
<SENT sid="45" pm="."><plain>The level of significance was set at P &lt; 0.05. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec><title><text><SENT sid="46" pm="."><plain>RESULTS </plain></SENT>
</text></title><p><text><SENT sid="47" pm="."><plain>This study included 192 cases (144 males, 48 females; mean age 72.8 Â± 7 years; 215 lesions) of early stage GCED and CGC. </plain></SENT>
<SENT sid="48" pm="."><plain>Among 192 cases, there were 6 GCED cases (5 males, 1 female; mean age 75.7 years; 6 lesions) and 186 CGC cases (139 males, 47 females; mean age 72.7 years; 209 lesions). </plain></SENT>
<SENT sid="49" pm="."><plain>Table 1 shows the clinicopathological findings of the patients with GCED and Table 2 shows results of the comparison between patients with GCED and CGC. </plain></SENT>
<SENT sid="50" pm="."><plain>Four cases who were checked for Helicobacter pylori (H. pylori) infection by H. pylori-immunoglobulin G were positive. </plain></SENT>
<SENT sid="51" pm="."><plain>No significant differences were observed in tumor location (U/M/L = 2/2/2 and 23/91/95 in GCED and CGC, respectively), mean tumor size (15.0 and 15.2 mm in GCED and CGC, respectively), and macroscopic types (flat or depressed type/ elevated type = 4/2 and 92/117 in GCED and CGC, respectively). </plain></SENT>
<SENT sid="52" pm="."><plain>Endoscopically, we could not find specific features of GCED or anticipate deep submucosal invasion (Figure 1). </plain></SENT>
<SENT sid="53" pm="."><plain>No lesion was diagnosed as GCED by examination of biopsy specimens. </plain></SENT>
<SENT sid="54" pm="."><plain>Regarding the depth of tumor invasion, the total submucosal invasion rate was significantly higher in GCED than CGC (66.6% vs 11.4%, P &lt; 0.01). </plain></SENT>
<SENT sid="55" pm="."><plain>Positive rates for lymphatic and venous invasion were significantly higher in GCED than CGC (33.3% vs 2.3% and 66.6% vs 0.4%, P &lt; 0.01). </plain></SENT>
<SENT sid="56" pm="."><plain>Therefore, the curative resection rate was significantly lower in GCED than CGC (16.7% vs 89.0%, P &lt; 0.01). </plain></SENT>
<SENT sid="57" pm="."><plain>Moreover, when comparing only SM invasive cancer, the positive rate for venous invasion was significantly higher in GCED than CGC (100% vs 4.2%, P &lt; 0.01) and the curative resection rate was significantly lower in GCED than CGC (0% vs 50%, P &lt; 0.01). </plain></SENT>
<SENT sid="58" pm="."><plain>In 2 of the 6 GCED cases, additional surgery was performed (case 3: T1N0M0, stage IA; case 6: T1N1M0, stage IIA). </plain></SENT>
<SENT sid="59" pm="."><plain>Recurrence or metastasis was not seen in any of the 4 GCED cases that were followed from 28 to 51 mo (median 40 mo). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><text><SENT sid="60" pm="."><plain>Clinicopathological findings for patients with gastric cancer with enteroblastic differentiation </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>Case </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>5 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>6 </plain></SENT>
</text></td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>Age, yr </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>61 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>77 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>78 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>75 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>80 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>83 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>Male/female </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>Male </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>Male </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>Male </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>Male </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>Female </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>Male </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>Tumor location: U/M/L </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>L </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>M </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>U </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>U </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>L </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>M </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>Tumor size, mm </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>8 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>11 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>14 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>18 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>6 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>36 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>Macroscopic type </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>0-IIc </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>0-IIc </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>0-IIc </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>0-IIa </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>0-IIc </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>0-IIa + I </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>H. pylori infection </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>HPIgG+ </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>HPIgG+ </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>HPIgG- </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>NA </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>HPIgG+ </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>HPIgG+ </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>Procedure method </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>ESD </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>ESD </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>ESD with additional surgery </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>ESD </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>ESD </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>ESD with additional surgery </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>Depth of invasion (Î¼m) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>M </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>SM (1500) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>SM (1000) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>SM (200) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>M </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>SM (2000) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>Lymphatic invasion </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>(+) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>Venous invasion </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>(+) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>Observation period (mo) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>51, ANED </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>42, ANED </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>N/A </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>38, ANED </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>N/A </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>28, ANED </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>Immunohistochemical analysis </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>AFP </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>(-) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>Glypican3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>(+) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>SALL4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>(-) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>MUC2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>(-) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>MUC5AC </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>(-) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>MUC6 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>(+) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>CD10 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>(+) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>P53 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>(-) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>(+) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>(-) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="202" pm="."><plain>U: Upper third of stomach; M: Middle third of stomach; L: Lower third of stomach; H. pylori: Helicobacter pylori; IgG: Immunoglobulin G; ESD: Endoscopic submucosal dissection; M: Mucosa; SM: Submucosa; ANED: Alive with no evidence of disease; N/A: Not applicable; AFP: Alpha-fetoprotein. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="F1" position="float"><label>Figure 1</label><caption><p><text><SENT sid="203" pm="."><plain>Endoscopic findings (case 1). </plain></SENT>
<SENT sid="204" pm="."><plain>A: Endoscopic examination with a white light image revealed a 10 mm reddish depressed lesion on the posterior wall in the middle third of the stomach. </plain></SENT>
<SENT sid="205" pm="."><plain>There were no specific features of deep submucosal invasion; B: Endoscopic examination with narrow band imaging (NBI). </plain></SENT>
<SENT sid="206" pm="."><plain>A demarcation line was clearly present between a depressed lesion and the surrounding mucosa; C: Magnifying endoscopy with NBI findings. </plain></SENT>
<SENT sid="207" pm="."><plain>Within the demarcation line, an irregular microvascular pattern (bizarre and tortuous vessel) and an irregular microsurface pattern (curved marginal crypt epithelium) are demonstrated. </plain></SENT>
<SENT sid="208" pm="."><plain>There were no specific features of GCED. </plain></SENT>
<SENT sid="209" pm="."><plain>GCED: Gastric cancer with enteroblastic differentiation. </plain></SENT>
</text></p></caption><graphic xlink:href="WJG-22-8203-g001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><text><SENT sid="210" pm="."><plain>Results of comparison between patients with gastric cancer with enteroblastic differentiation and conventional gastric cancer n (%) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>GCED </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>CGC </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>P value </plain></SENT>
</text></td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>Number of lesions, n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>6 (2.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>209 (97.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>N/A </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>Age, yr; median (range) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>75.7 (61-83) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>72.7 (40-92) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>0.39 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>Male/female </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>5/1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>139/47 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>0.63 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>Tumor location: U/M/L </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>2/2/2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>23/91/95 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>0.24 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>Tumor size, mm, mean (range) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>15.0 (6-36) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>15.2 (2-60) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>0.96 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>Macroscopic type: elevated type/flat or depressed type </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>2/4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>92/117 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>0.60 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>Ulceration </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>0 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>19 (9.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>0.43 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>Depth of invasion: M/SM </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>2/4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>185/24 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>&lt; 0.01 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>Rate of submucosal invasive cancer </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>66.60% </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>11.40% </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>Median SM invasive depth, Î¼m (range) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>1500(200-2000) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>795.8(100-5000) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>0.40 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>Lymphatic invasion </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>2 (33.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>5 (2.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>&lt; 0.01 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>Venous invasion </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>4 (66.6) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>1 (0.4) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>&lt; 0.01 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>Positive horizontal margin </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>0 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>9 (4.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>0.60 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>Positive vertical margin </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>1 (16.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>5 (2.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>&lt; 0.05 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>Curative resection1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>1 (16.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>186 (89.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>&lt; 0.01 </plain></SENT>
</text></td></tr><tr><td colspan="4" align="left" rowspan="1"><text><SENT sid="273" pm="."><plain>The following is a comparison only for SM invasive cancer </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>Number of SM invasive lesions, n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>24 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>N/A </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>Lymphatic invasion </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>1 (25) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>5 (20.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>0.88 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>Venous invasion </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>4 (100) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>1 (4.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>&lt; 0.01 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>Positive horizontal margin </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>0 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>1 (4.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>0.33 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>Positive vertical margin </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>1 (16.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>2 (8.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>0.55 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>Curative resection1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>0 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>12 (50) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>&lt; 0.01 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="T2FN1"><label>1</label><p><text><SENT sid="298" pm="."><plain>Curative resection was according to Gastric Cancer Treatment Guidelines 2010 or 2014 provided by the Japanese Gastric Cancer Association. </plain></SENT>
<SENT sid="299" pm="."><plain>GCED: Gastric cancer with enteroblastic differentiation; CGC: Conventional gastric cancer (well or moderately differentiated carcinoma); U: Upper third of stomach; M: Middle third of stomach; L: Lower third of stomach; M: Mucosa; SM: Submucosa. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="300" pm="."><plain>Histological examination of GCED demonstrated the presence of tubulopapillary carcinoma with clear cytoplasm at the deeper part of the mucosa and submucosa by lymphatic and/or venous invasion, and there was no severe stromal reaction. </plain></SENT>
<SENT sid="301" pm="."><plain>In all GCED cases, the superficial mucosal layer was covered with a conventional tubular adenocarcinoma (Figure 2). </plain></SENT>
<SENT sid="302" pm="."><plain>All GCED patients were positive for at least one of three enteroblastic lineage markers (AFP, Glypican 3, SALL 4). </plain></SENT>
<SENT sid="303" pm="."><plain>Glypican 3 was the most sensitive marker (positivity, 83.3%). </plain></SENT>
<SENT sid="304" pm="."><plain>Four cases were classified as having the gastrointestinal phenotype (4/6; 66.7%), and two as the intestinal type (2/6; 33.3%) according to combinations of the expression of CD10, MUC2, MUC5AC, and MUC6 (Figure 3). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" position="float"><label>Figure 2</label><caption><p><text><SENT sid="305" pm="."><plain>Histological examination of the resected specimens with hematoxylin and eosin stain (case 1). </plain></SENT>
<SENT sid="306" pm="."><plain>A and B: The superficial mucosal layer was covered with a well differentiated adenocarcinoma; B-D: Carcinoma cells with clear cytoplasm had tubulopapillary growth, resembling the primitive gut. </plain></SENT>
<SENT sid="307" pm="."><plain>These carcinoma cells arose from the deeper part of the mucosal layer and invaded into the submucosal layer by venous invasion. </plain></SENT>
<SENT sid="308" pm="."><plain>There was no severe stromal reaction at the submucosal layer. </plain></SENT>
<SENT sid="309" pm="."><plain>Pathological diagnosis was as follows: stomach (ESD): adenocarcinoma with enteroblastic differentiation, 0-IIc, 11 mm Ã 9 mm, well-differentiated carcinoma &gt; moderately-differentiated carcinoma, papillary adenocarcinoma, SM (1500 Î¼m), ly (-), v (+), HM0, VM0. </plain></SENT>
<SENT sid="310" pm="."><plain>SM: Submucosa; ESD: Endoscopic submucosal dissection. </plain></SENT>
</text></p></caption><graphic xlink:href="WJG-22-8203-g002"/></fig></SecTag><SecTag type="FIG"><fig id="F3" position="float"><label>Figure 3</label><caption><p><text><SENT sid="311" pm="."><plain>Immunohistochemical examination of resected specimens (case 1). </plain></SENT>
<SENT sid="312" pm="."><plain>A: MUC2; B: MUC5AC; C: MUC6; D: CD10; E: AFP; F: Glypican 3; G: SALL 4. </plain></SENT>
<SENT sid="313" pm="."><plain>The lesion had focal positivity for MUC6, diffuse positivity for CD10, weak positivity for Glypican 3 and negative staining for MUC2, MUC5AC, AFP and SALL4. </plain></SENT>
</text></p></caption><graphic xlink:href="WJG-22-8203-g003"/></fig></SecTag></sec></SecTag><SecTag type="DISCUSS"><sec><title><text><SENT sid="314" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="315" pm="."><plain>AFP was initially found in 1956 and is a fetal serum protein produced mainly in the fetal liver and yolk sac. </plain></SENT>
<SENT sid="316" pm="."><plain>After birth, AFP rapidly disappears and is not detected in the serum of healthy adults[7]. </plain></SENT>
<SENT sid="317" pm="."><plain>The serum level of AFP is increased in some patients with hepatocellular carcinoma (HCC) or yolk sac tumor. </plain></SENT>
<SENT sid="318" pm="."><plain>In clinical practice, AFP has been considered to be a useful tumor marker in screening or monitoring patients with HCCs or yolk sac tumors. </plain></SENT>
<SENT sid="319" pm="."><plain>However, some diseases other than HCCs and yolk sac tumor were also associated with high serum levels of AFP, and gastric cancer is one of the most common[2,8-15]. </plain></SENT>
<SENT sid="320" pm="."><plain>Since the first report of AFPGC by Bourreille et al[16] in 1970, many cases have been reported, and the specifics of this disease have been gradually clarified. </plain></SENT>
</text></p><p><text><SENT sid="321" pm="."><plain>Histologically, typical AFPGC has a liver-like structure and has been frequently reported as hepatoid adenocarcinoma[17-20]. </plain></SENT>
<SENT sid="322" pm="."><plain>However, there are also histologic types of carcinoma other than hepatoid adenocarcinoma. </plain></SENT>
<SENT sid="323" pm="."><plain>In 1994, Matsunou et al[1] reported two cases of AFP-producing gastric carcinoma with enteroblastic differentiation (AFP-producing clear cell gastric carcinoma), and the tumor characteristics were as follows: (1) columnar carcinoma cells growing primarily in tubulopapillary and glandular patterns; (2) abundant glycogen, but no mucin production in the clear cytoplasm; (3) gut hormone-containing cells scattered among clear carcinoma cells; (4) carcinoma cells producing oncofetal glycoproteins such as AFP and CEA; and (5) ultrastructurally, carcinoma cells showing well-developed microvilli with core filaments, whose rootlets formed occasional terminal webs, consistent with absorptive epithelium of fetal intestine or enteroblastic differentiation. </plain></SENT>
<SENT sid="324" pm="."><plain>Motoyama et al[21] proposed that AFPGCs should be divided into three subtypes: (1) hepatoid type; (2) yolk sac type; and (3) fetal gastrointestinal type. </plain></SENT>
<SENT sid="325" pm="."><plain>The fetal gastrointestinal type is thought to be equivalent to GCED[1,3]. </plain></SENT>
<SENT sid="326" pm="."><plain>It is said that most AFPGCs have various mixtures of these histologic types and CGC. </plain></SENT>
<SENT sid="327" pm="."><plain>Kinjo et al[2] also reported that in a histologic type of submucosal invasive cancer of AFPGC, the positivity rates for CGC and GCED in the mucosal component were significantly higher than in the invasive component. </plain></SENT>
<SENT sid="328" pm="."><plain>On the other hand, hepatoid gastric carcinoma (HGC) was significantly positive in the invasive component. </plain></SENT>
<SENT sid="329" pm="."><plain>In this study, pathological findings in all GCED cases showed that the mucosal layer was composed of conventional tubular adenocarcinoma and GCED. </plain></SENT>
<SENT sid="330" pm="."><plain>In addition, the superficial mucosal layer was covered with a conventional tubular adenocarcinoma, and there were no findings of GCED components exposed to the superficial layer. </plain></SENT>
<SENT sid="331" pm="."><plain>Therefore, since we could only collect superficial mucosal layer tissue for the biopsy specimens, we felt that GCED could not be diagnosed by examination of biopsy specimens. </plain></SENT>
<SENT sid="332" pm="."><plain>The GCED component exists only in the deeper part of the mucosa to the submucosa by lymphatic and/or venous invasion but not in any other histological type of AFPGC (HGC and yolk sac type). </plain></SENT>
<SENT sid="333" pm="."><plain>As in previous reports[2,4] these findings suggested that GCED could be thought to develop from CGC and then gradually develop hepatoid features during the process of tumor invasion and proliferation. </plain></SENT>
<SENT sid="334" pm="."><plain>We considered that there is a possibility that early stage GCED represents the early developmental stage of AFPGC, which has various mixtures of histological types. </plain></SENT>
</text></p><p><text><SENT sid="335" pm="."><plain>Endoscopically, we diagnose the depth of invasion according to endoscopic features of gastric cancers with deep submucosal invasion (â¥ 500 Î¼m in depth), such as remarkable redness, uneven surface, margin elevation, ulceration, and enlarged folds[22]. </plain></SENT>
<SENT sid="336" pm="."><plain>However, we could not anticipate the presence of deep submucosal invasion because none of these findings were revealed in our 6 GCED cases. </plain></SENT>
<SENT sid="337" pm="."><plain>The reason may be that there were few macroscopic changes in endoscopic morphology because the main submucosal invasive form of GCED depends on lymphatic and/or venous invasion and there were no severe stromal reactions. </plain></SENT>
</text></p><p><text><SENT sid="338" pm="."><plain>In previous reports, AFPGC was usually associated with a poor prognosis with a high incidence of lymphatic invasion, venous invasion, and synchronous and metachronous liver metastasis[23-25]. </plain></SENT>
<SENT sid="339" pm="."><plain>Hirasaki et al[26] studied 24 cases of AFP-producing early gastric cancer and reported that liver metastasis was seen in 2 cases (8.3%) and lymph node metastasis was seen in 18 of 24 cases (75.0%). </plain></SENT>
<SENT sid="340" pm="."><plain>From these results, they suggested that lymph node metastasis should be generally taken into consideration in AFP-producing early gastric cancer even if lymph node swelling is not seen on diagnostic imaging and that such patients should be under close periodic observation. </plain></SENT>
<SENT sid="341" pm="."><plain>Furthermore, Adachi et al[23] studied 270 cases of AFPGC and reported that there were 61 patients who underwent curative gastrectomy for stage I or II AFPGC, and that 39 of those patients (64%) were alive during a median follow-up period of 27 mo. </plain></SENT>
<SENT sid="342" pm="."><plain>From these results, it is difficult to say that the prognosis was good. </plain></SENT>
<SENT sid="343" pm="."><plain>Although in this study the mean diameters of GCED and CGC were about the same, comparisons of M and SM invasive cancer, positive rates of lymphatic and venous invasion, and non-curative resection rates were significantly higher in GCED than CGC. </plain></SENT>
<SENT sid="344" pm="."><plain>Furthermore, when comparing only SM invasive cancer, the positive rate of venous invasion was significantly higher in GCED than CGC (100% vs 4.2%, P &lt; 0.01). </plain></SENT>
<SENT sid="345" pm="."><plain>Although lymph node swelling cannot be seen on diagnostic imaging, lymph node metastasis occurred in 1 of 2 GCED cases who underwent additional surgery. </plain></SENT>
<SENT sid="346" pm="."><plain>In addition, although all of the 4 GCED cases for whom we could follow their complete progress were alive during the median follow-up period of 40 mo, 5 of 6 GCED cases (83.3%; 4 of 4 SM invasive cancer, 100%) had endoscopic non-curative resection because of deep submucosal invasion, lymphatic and/or venous invasion, and a positive margin. </plain></SENT>
<SENT sid="347" pm="."><plain>Therefore, we think that GCED, as well as AFPGC, may have a high incidence of liver and lymph node metastasis because of the high level of affinity to vessels and is associated with a poor prognosis in comparison with CGC. </plain></SENT>
<SENT sid="348" pm="."><plain>In this study, 2 of 5 cases who had endoscopic non-curative resection were followed up without additional surgery. </plain></SENT>
<SENT sid="349" pm="."><plain>One of the 5 cases had additional surgery and the remaining 2 were followed elsewhere. </plain></SENT>
<SENT sid="350" pm="."><plain>Although the 2 cases that we are following are alive without a recurrence (case 2: 42 mo, case 5: 38 mo), it is thought that close periodic observation is strictly required in such cases. </plain></SENT>
</text></p><p><text><SENT sid="351" pm="."><plain>The present study had some limitations. </plain></SENT>
<SENT sid="352" pm="."><plain>Since GCED is a disease with a very low incidence rate, the number of patients was small. </plain></SENT>
<SENT sid="353" pm="."><plain>Furthermore, the data were collected retrospectively in a single medical center, which may produce selection bias. </plain></SENT>
</text></p><p><text><SENT sid="354" pm="."><plain>In conclusion, GCED is rare, but has distinct clinicopathological features, especially in terms of high malignant potential and difficulty in preoperative diagnosis by biopsy specimens and prediction of submucosal invasion by endoscopic findings. </plain></SENT>
<SENT sid="355" pm="."><plain>It is necessary for endoscopists and pathologists to be aware of the clinicopathological features of such a rare and highly malignant type of cancer. </plain></SENT>
<SENT sid="356" pm="."><plain>In addition, when we detect specific histological findings for GCED with hematoxylin and eosin stain, immunohistochemical examination should be performed to make a precise diagnosis. </plain></SENT>
<SENT sid="357" pm="."><plain>However, there has been no report that evaluated a large number of cases. </plain></SENT>
<SENT sid="358" pm="."><plain>Further investigations are needed to elucidate the natural history of GCED by assessing the long-term outcome and establishing optimal treatment approaches for GCED. </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec><title><text><SENT sid="359" pm="."><plain>COMMENTS </plain></SENT>
</text></title><sec><title><text><SENT sid="360" pm="."><plain>Background </plain></SENT>
</text></title><p><text><SENT sid="361" pm="."><plain>Gastric cancer with enteroblastic differentiation (GCED) was proposed as a very rare variant of alpha-fetoprotein-producing gastric cancer (AFPGC). </plain></SENT>
<SENT sid="362" pm="."><plain>In previous reports, AFPGC was usually associated with a poor prognosis with a high incidence of lymphatic invasion, venous invasion, and synchronous and metachronous liver metastasis. </plain></SENT>
<SENT sid="363" pm="."><plain>Recently, with the advent and widespread use of endoscopic submucosal dissection (ESD), indications for endoscopic treatment of early stage gastric cancer have been expanding rapidly. </plain></SENT>
<SENT sid="364" pm="."><plain>Therefore, it is necessary for endoscopists to know the clinicopathological features of various histological types of early gastric cancer. </plain></SENT>
<SENT sid="365" pm="."><plain>However, the clinicopathological features and the optimal treatment approaches of GCED have not been well elucidated. </plain></SENT>
<SENT sid="366" pm="."><plain>In this study, we investigated clinicopathological features of early stage of GCED. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="367" pm="."><plain>Research frontiers </plain></SENT>
</text></title><p><text><SENT sid="368" pm="."><plain>There are few reports about GCED. </plain></SENT>
<SENT sid="369" pm="."><plain>Most of these are case reports, and there is no report that focused on the early stage of GCED. </plain></SENT>
<SENT sid="370" pm="."><plain>In these earlier reported cases, GCED was histologically characterized as having a primitive intestine-like structure composed of cuboidal or columnar cells with clear cytoplasm, and GCED showed aggressive behavior such as lymphatic and venous invasion, lymph node metastasis, and liver metastasis. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="371" pm="."><plain>Innovations and breakthroughs </plain></SENT>
</text></title><p><text><SENT sid="372" pm="."><plain>The results of this study contribute to clarifying the clinicopathological features of early stage GCED by comparisons with the early stage of conventional gastric cancer (CGC), including well or moderately differentiated carcinoma. </plain></SENT>
<SENT sid="373" pm="."><plain>In this study, even if it is early stage cancer, GCED has distinct clinicopathological features, especially in terms of high malignant potential with a high incidence of lymphatic and venous invasion, difficulty in preoperative diagnosis by biopsy specimens and prediction of submucosal invasion by endoscopic findings. </plain></SENT>
<SENT sid="374" pm="."><plain>In addition, Glypican 3 was the most sensitive marker for GCED (positivity, 83.3%), immunohistochemically. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="375" pm="."><plain>Applications </plain></SENT>
</text></title><p><text><SENT sid="376" pm="."><plain>If the authors detect specific histological findings for GCED with hematoxylin and eosin stain, immunohistochemical examination, especially Glypican 3 should be performed to make a precise diagnosis. </plain></SENT>
<SENT sid="377" pm="."><plain>However, there has been no report that evaluated a large number of cases. </plain></SENT>
<SENT sid="378" pm="."><plain>Further investigations are needed to elucidate the natural history of GCED by assessing the long-term outcome and establishing optimal treatment approaches for GCED. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="379" pm="."><plain>Terminology </plain></SENT>
</text></title><p><text><SENT sid="380" pm="."><plain>ESD is a well established technique of endoscopic resection that allows for en bloc removal of GI epithelial lesions. </plain></SENT>
<SENT sid="381" pm="."><plain>Glypican 3, it is an oncofetal protein that is expressed in the human fetal liver and placenta. </plain></SENT>
<SENT sid="382" pm="."><plain>It was discovered as a potential serological and histochemical marker whose expression is specific for hepatocellular carcinoma. </plain></SENT>
<SENT sid="383" pm="."><plain>SALL 4, it is an oncofetal protein that is expressed in the human fetal liver and silenced in the adult liver, but it is reexpressed in a subgroup of patients who have hepatocellular carcinoma and an unfavorable prognosis. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="384" pm="."><plain>Peer-review </plain></SENT>
</text></title><p><text><SENT sid="385" pm="."><plain>This most remarkable point of this manuscript is the analysis of the influence of this rare type of tumor and its bad prognosis in comparison to the conventional one that justifies the research in this subtype. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><fn-group><fn><p><text><SENT sid="386" pm="."><plain>Manuscript source: Unsolicited manuscript </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="387" pm="."><plain>Specialty type: Gastroenterology and hepatology </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="388" pm="."><plain>Country of origin: Japan </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="389" pm="."><plain>Peer-review report classification </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="390" pm="."><plain>Grade A (Excellent): 0 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="391" pm="."><plain>Grade B (Very good): B </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="392" pm="."><plain>Grade C (Good): 0 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="393" pm="."><plain>Grade D (Fair): 0 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="394" pm="."><plain>Grade E (Poor): 0 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="395" pm="."><plain>Institutional review board statement: This study was reviewed and approved by the Juntendo University School of Medicine Institutional Review Board. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="396" pm="."><plain>Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by verbal consent. </plain></SENT>
<SENT sid="397" pm="."><plain>Individuals canât be identified according to the data presented. </plain></SENT>
</text></p></fn><fn fn-type="COI-statement"><p><text><SENT sid="398" pm="."><plain>Conflict-of-interest statement: All authors declare that there is no conflict of interest with the paper presented. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="399" pm="."><plain>Data sharing statement: Informed consent for data sharing was not obtained but the presented data are anonymized and the risk of identification is low. </plain></SENT>
<SENT sid="400" pm="."><plain>No additional data are available. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="401" pm="."><plain>Peer-review started: March 18, 2016 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="402" pm="."><plain>First decision: July 12, 2016 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="403" pm="."><plain>Article in press: August 8, 2016 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="404" pm="."><plain>P- Reviewer: Varona MA S- Editor: Gong ZM L- Editor: A E- Editor: Wang CH </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="405" pm="."><plain>1MatsunouHKonishiFJalalREYamamichiNMukawaAAlpha-fetoprotein-producing gastric carcinoma with enteroblastic differentiationCancer1994735345407507794 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="406" pm="."><plain>2KinjoTTaniguchiHKushimaRSekineSOdaISakaMGotodaTKinjoFFujitaJShimodaTHistologic and immunohistochemical analyses of Î±-fetoprotein--producing cancer of the stomachAm J Surg Pathol201236566522173117 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="407" pm="."><plain>3YamabukiTOmiMYonemoriAMisuKInomataHAbikoYMoriMNiheiKGastrointestinal Obstruction due to Solitary Lymph Node Recurrence of Alpha-Fetoprotein-Producing Gastric Carcinoma with Enteroblastic DifferentiationCase Rep Gastroenterol201481624574942 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="408" pm="."><plain>4MurakamiTYaoTMitomiHMorimotoTUeyamaHMatsumotoKSaitoTOsadaTNagaharaAWatanabeSClinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 casesGastric Cancer20161949850725893262 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="409" pm="."><plain>5Japanese Gastric Cancer AssociationJapanese gastric cancer treatment guidelines 2010 (ver. </plain></SENT>
<SENT sid="410" pm="."><plain>3)Gastric Cancer20111411312321573742 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="411" pm="."><plain>6Japanese Gastric Cancer AssociationJapanese gastric cancer treatment guidelines 2014 (ver. </plain></SENT>
<SENT sid="412" pm="."><plain>4)Gastric Cancer2016Epub ahead of print </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="413" pm="."><plain>7BergstrandCGCzarBDemonstration of a new protein fraction in serum from the human fetusScand J Clin Lab Invest1956817413351554 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="414" pm="."><plain>8HamanakaWYonedaSShirakusaTShirahamaHTashiroYIwasakiAShiraishiTTsuruHAlpha-fetoprotein (AFP)-producing adrenocortical carcinoma--long survival with various therapeutic strategies including a lung resection: report of a caseSurg Today20083827527818307006 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="415" pm="."><plain>9IsonishiSOguraAKiyokawaTSuzukiMKunitoSHiramaMTachibanaTOchiaiKTanakaTAlpha-fetoprotein (AFP)-producing ovarian tumor in an elderly womanInt J Clin Oncol200914707319225928 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="416" pm="."><plain>10YamagataTYamagataYNakanishiMMatsunagaKMinakataYIchinoseMA case of primary lung cancer producing alpha-fetoproteinCan Respir J20041150450615505704 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="417" pm="."><plain>11HockingGRShembreyMHayDOstÃ¶rAGAlpha-fetoprotein-producing adenocarcinoma of the sigmoid colon with possible hepatoid differentiationPathology1995272772798532396 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="418" pm="."><plain>12KodamaTKameyaTHirotaTShimosatoYOhkuraHMukojimaTKitaokaHProduction of alpha-fetoprotein, normal serum proteins, and human chorionic gonadotropin in stomach cancer: histologic and immunohistochemical analyses of 35 casesCancer198148164716556169423 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="419" pm="."><plain>13KoyamaSEbiharaTOsugaTHistologic and immunohistochemical studies of alpha-fetoprotein (AFP)-producing gastric carcinomaGastroenterol Jpn1987224194272444485 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="420" pm="."><plain>14MasuzawaMLeePKKamadaTAkeyamaTAbeHShimanoTMoriTMorinoHIshiguroSCarcinoembryonic antigen, alpha-fetoprotein and carcinoplacental alkaline phosphatase in gastric carcinoma metastatic to the liverCancer1977391175118071944 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="421" pm="."><plain>15NishimuraHOkamotoYTakahashiMFujitaTOccurrence of alpha-fetoprotein, Regan isoenzyme, and variant alkaline phosphatase in the serum of a patient with gastric cancerGastroenterology19767149749959676 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="422" pm="."><plain>16BourreilleJMetayerPSaugerFMatrayFFondimareA[Existence of alpha feto protein during gastric-origin secondary cancer of the liver]Presse Med197078127712785426134 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="423" pm="."><plain>17IshikuraHKirimotoKShamotoMMiyamotoYYamagiwaHItohTAizawaMHepatoid adenocarcinomas of the stomach. </plain></SENT>
<SENT sid="424" pm="."><plain>An analysis of seven casesCancer1986581191262423220 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="425" pm="."><plain>18YeMFTaoFLiuFSunAJHepatoid adenocarcinoma of the stomach: a report of three casesWorld J Gastroenterol2013194437444223885160 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="426" pm="."><plain>19YangJWangRZhangWZhuangWWangMTangCClinicopathological and prognostic characteristics of hepatoid adenocarcinoma of the stomachGastroenterol Res Pract2014201414058724669215 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="427" pm="."><plain>20LinCYYehHCHsuCMLinWRChiuCTClinicopathologial features of gastric hepatoid adenocarcinomaBiomed J201538656925163499 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="428" pm="."><plain>21MotoyamaTAizawaKWatanabeHFukaseMSaitoKalpha-Fetoprotein producing gastric carcinomas: a comparative study of three different subtypesActa Pathol Jpn1993436546617508672 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="429" pm="."><plain>22AbeSOdaIShimazuTKinjoTTadaKSakamotoTKusanoCGotodaTDepth-predicting score for differentiated early gastric cancerGastric Cancer201114354021327924 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="430" pm="."><plain>23AdachiYTsuchihashiJShiraishiNYasudaKEtohTKitanoSAFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patientsOncology2003659510112931013 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="431" pm="."><plain>24LiXDWuCPJiMWuJLuBShiHBJiangJTCharacteristic analysis of Î±-fetoprotein-producing gastric carcinoma in ChinaWorld J Surg Oncol20131124624083471 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="432" pm="."><plain>25LiuXChengYShengWLuHXuYLongZZhuHWangYClinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 casesJ Surg Oncol201010224925520740583 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="433" pm="."><plain>26HirasakiSTanimizuMTsuzukiTTsubouchiEHidakaSHyodoITajiriHSeronegative alpha-fetoprotein-producing early gastric cancer treated with endoscopic mucosal resection and additional surgeryIntern Med20044392693015575241 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
